Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00352885 · ClinicalTrials.gov registry record · Phase 4
Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00352885 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 20 participants.
The verdict
NCT00352885, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of an antidepressant in preventing or reducing depressive symptoms in people with melanoma who are receiving Interleukin-2 (IL-2) treatment.
Interventions
- DRUG Placebo
- DRUG Escitalopram
- DRUG IL-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-10-06 |
| Est. Completion | 2010-05-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00352885
The ClinicalTrials.gov registry entry for NCT00352885 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00352885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00352885 about?
NCT00352885 is a clinical study titled "Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment". This study will determine the effectiveness of an antidepressant in preventing or reducing depressive symptoms in people with melanoma who are receiving Interleukin-2 (IL-2) treatment.
What is the current status of trial NCT00352885?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2006-10-06. Estimated completion is 2010-05-17.
What interventions are being tested in trial NCT00352885?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG), IL-2 (DRUG).
Who is sponsoring clinical trial NCT00352885?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.